Cognition Therapeutics(CGTX) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Purchase, NY – May 7, 2024 – Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the first quarter ended March 31, 2024, and provided a business update. Cash and cash equivalents as of March 31, 2024 were approximately $34.7 million and total grant funds remaining from the NIA were $62.3 million. Cash and cash equivalents includes net proce ...